Artrya Limited (AU:AYA)
ASX:AYA
Want to see AU:AYA full AI Analyst Report?
Top Page
Artrya Limited
(Sydney:AYA)
Select Model
Select Model
Rating:54Neutral
Price Target:
AU$5.00
▲(21.95% Upside)
Action:Reiterated
Date:04/16/26
The score is held back primarily by weak financial performance—material operating losses and ongoing cash burn—despite a low-leverage balance sheet. Offsetting this, technicals are strong with the stock trading above key moving averages and positive momentum indicators. Valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Focused AI Cardiovascular Software
Artrya's core product is AI-driven coronary angiography analysis, a specialized clinical workflow tool. That focused clinical niche aligns with structural demand for decision‑support in cardiology, supports recurring hospital adoption, and can create durable commercial hooks once validated and integrated.
Negative Factors
Sustained Cash Burn
Consistent negative operating and free cash flow indicate the business remains cash‑consuming. Over the medium term this creates reliance on external capital, risks dilution, and can constrain the pace of commercial rollout or regulatory activities if funding becomes scarce.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused AI Cardiovascular Software
Artrya's core product is AI-driven coronary angiography analysis, a specialized clinical workflow tool. That focused clinical niche aligns with structural demand for decision‑support in cardiology, supports recurring hospital adoption, and can create durable commercial hooks once validated and integrated.
Read all positive factors
Artrya Limited (AYA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$780.32M
Dividend YieldN/A
Average Volume (3M)878.02K
Price to Earnings (P/E)―
Beta (1Y)2.20
Revenue Growth123.08%
EPS Growth5.34%
CountryAU
Employees43
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.17
Shares Outstanding162,906,620
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.10Price Target Upside48.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)AU$6.45M
Artrya Limited Business Overview & Revenue Model
Company Description
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages...
How the Company Makes Money
null...
Artrya Limited Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
15
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.00K | 28.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.60M | -15.99M | -13.25M | -552.00K | -202.00K | -38.51K |
| EBITDA | -21.14M | -16.21M | -13.96M | -10.51M | -16.40M | -4.01M |
| Net Income | -19.71M | -16.41M | -14.00M | -11.14M | -17.16M | -4.08M |
Balance Sheet | ||||||
| Total Assets | 92.19M | 23.68M | 19.01M | 33.09M | 43.87M | 52.22M |
| Cash, Cash Equivalents and Short-Term Investments | 76.67M | 11.33M | 7.28M | 20.41M | 35.56M | 50.13M |
| Total Debt | 546.00K | 624.00K | 949.00K | 1.21M | 1.37M | 84.42K |
| Total Liabilities | 2.84M | 2.39M | 2.21M | 2.53M | 3.23M | 1.17M |
| Stockholders Equity | 89.35M | 21.29M | 16.80M | 30.56M | 40.64M | 51.05M |
Cash Flow | ||||||
| Free Cash Flow | -21.38M | -14.53M | -15.41M | -16.69M | -15.99M | -3.55M |
| Operating Cash Flow | -21.08M | -14.27M | -15.41M | -10.74M | -9.61M | -1.49M |
| Investing Cash Flow | -30.30M | 7.00K | 2.71M | 16.27M | -26.59M | -1.86M |
| Financing Cash Flow | 90.07M | 18.46M | -299.00K | -245.00K | 38.53M | 14.10M |
Artrya Limited Technical Analysis
Positive
4.10
Price Trends
4.50
Positive
3.88
Positive
3.61
Positive
Market Momentum
0.05
Positive
55.80
Neutral
60.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AYA, the sentiment is Positive. The current price of 4.1 is below the 20-day moving average (MA) of 4.71, below the 50-day MA of 4.50, and above the 200-day MA of 3.61, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 55.80 is Neutral, neither overbought nor oversold. The STOCH value of 60.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:AYA.
Artrya Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$22.90M | 27.05 | 7.57% | ― | 31.36% | ― | |
54 Neutral | AU$780.32M | -29.99 | -35.63% | ― | 123.08% | 5.34% | |
52 Neutral | AU$42.15M | -7.79 | -14.19% | ― | 0.03% | -5.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$63.35M | -8.12 | -59.96% | ― | ― | ― | |
42 Neutral | AU$6.81M | -0.75 | 152.58% | ― | -57.91% | -9.02% |
* Healthcare Sector Average
AU:AYA
Artrya Limited
4.79
4.18
685.25%
AU:RHT
Resonance Health Ltd
0.05
0.01
37.14%
AU:BMT
Beamtree Holdings Ltd
0.15
-0.14
-48.21%
AU:SHG
Singular Health Group Ltd
0.20
-0.18
-46.67%
AU:HIQ
HitIQ Limited
0.01
>-0.01
-37.50%
Artrya Limited Corporate Events
Artrya Director Increases Indirect Shareholding Through Option Exercise
Jun 18, 2026
Artrya Limited has disclosed a change in the indirect shareholding of director Bernie Ridgeway, following the exercise of stock options held through Wear Services Pty Ltd , an entity where he serves as director and beneficiary. The transaction, da...
Artrya Seeks ASX Quotation for 1.75 Million New Shares
Jun 18, 2026
Artrya Limited has applied for quotation of 1,750,000 new ordinary fully paid shares on the Australian Securities Exchange. The securities, issued on June 18, 2026, arise from the exercise of options or conversion of other convertible instruments ...
Artrya issues 1.75m shares on option exercise and confirms regulatory compliance
Jun 18, 2026
Artrya Limited has issued 1,750,000 fully paid ordinary shares following the exercise of vested unlisted options linked to senior leadership, including an associate of co-founder and CEO John Konstantopoulos and an entity associated with director ...
Artrya Seeks ASX Quotation for Over 1.3 Million New Shares
Jun 2, 2026
Artrya Limited has applied to the ASX for quotation of 1,357,122 additional ordinary fully paid shares, issued on 1 June 2026, under an Appendix 2A filing. The new securities arise from the exercise or conversion of existing options or other conve...
Artrya Issues New Shares Following Cashless Exercise of Options
Jun 2, 2026
Artrya Limited has issued 1,357,122 fully paid ordinary shares following the cashless exercise of unlisted options, while 642,878 unlisted options have lapsed as part of the same transaction. The company has lodged the necessary documentation to s...
Artrya advances U.S. Salix rollout and readies coronary flow module for FDA submission
Apr 30, 2026
Artrya reported progress in the commercial rollout of its Salix platform in the U.S., with full integration across five Tanner Health hospitals and increasing scan volumes beginning to generate fee-per-scan revenue. Integration and onboarding work...
Artrya Director Increases Shareholding Through $500,000 Option Exercise
Apr 14, 2026
Artrya Limited has disclosed a change in director Bernie Ridgeway’s interests following the exercise of options. Through Wear Services Pty Ltd, Ridgeway converted 500,000 options at an exercise price of $1.00 each into ordinary shares, repre...
Artrya seeks ASX quotation for 500,000 new ordinary shares
Apr 14, 2026
Artrya Limited has applied for quotation on the ASX of 500,000 new ordinary fully paid shares, with an issue date of 14 April 2026 under its existing ticker AYA. The securities arise from the exercise or conversion of options or other convertible ...
Artrya Issues New Shares on Director Option Exercise and Files Cleansing Notice
Apr 14, 2026
Artrya Limited has issued 500,000 fully paid ordinary shares following the exercise of vested options by director Bernie Ridgeway, and will seek quotation of the new shares on the ASX alongside an updated director interest notice. The company has ...
Artrya Seeks ASX Quotation for 1.2 Million New Shares
Apr 8, 2026
Artrya Limited has applied to the Australian Securities Exchange for quotation of 1,215,476 new ordinary fully paid shares, to be listed under its existing ticker AYA. The new securities result from the exercise or conversion of existing options o...
Artrya Issues Over 1.2 Million New Shares on Option Exercises
Apr 8, 2026
Artrya Limited has issued 1,215,476 fully paid ordinary shares following the exercise of vested options and performance rights, expanding its share capital on 8 April 2026. The company has applied for quotation of the new shares on the ASX and con...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.